Novartis International AG, a Swiss based pharmaceutical firm, has derived a positive outcome from MONALEESA-7 – the phase III clinical experiment for Kisqali used in the treatment of metastatic breast cancer in premenopausal women. According to the firm, the trial was inclusive of a few premenopausal females who were treated with Kisqali along with goserelin and aromatase inhibitors. The treatment depicted a response as early as three weeks as compared to endocrine and goserelin treatment alone.
Sources have claimed that Median PFS (progression-free survival) for Novartis’s ribociclib regimen was approximately 23.8 months over 13 months for endocrine plus goserelin treatment alone. During the first eight weeks, premenopausal women consuming Kisqali exhibited an improvement in the pain symptoms and benefited for an elongated span as compared to those who were provided with endocrine & goserelin treatment alone.
It has been reported that Novartis is planning to discuss the clinical outcomes of its Phase III trials with health authoritative bodies across the globe to expand the scope of effectively treating female patients suffering from breast cancers with the newly tested drug. Earlier in March this year, the U.S. had already approved the use of Kisqali along with aromatase inhibitor for treating postmenopausal female patients suffering from metastatic breast cancer.
Researchers have apparently emphasized the significance of the drug in effectively treating breast cancer, stating that it has the ability to slow the growth of cancer tumors by connecting with two kinases referred as CDK6 and CDK4, which help cancer cells to proliferate after they become over-active.
According to authentic sources, the drug has also been cleared by the European Commission as an initial endocrine mode of treating the postmenopausal women, who are suffering from metastatic breast cancer, along with aromatase inhibitor. However, the drug is not yet officially approved for treatment.
Sources have claimed that Median PFS (progression-free survival) for Novartis’s ribociclib regimen was approximately 23.8 months over 13 months for endocrine plus goserelin treatment alone. During the first eight weeks, premenopausal women consuming Kisqali exhibited an improvement in the pain symptoms and benefited for an elongated span as compared to those who were provided with endocrine & goserelin treatment alone.
It has been reported that Novartis is planning to discuss the clinical outcomes of its Phase III trials with health authoritative bodies across the globe to expand the scope of effectively treating female patients suffering from breast cancers with the newly tested drug. Earlier in March this year, the U.S. had already approved the use of Kisqali along with aromatase inhibitor for treating postmenopausal female patients suffering from metastatic breast cancer.
Researchers have apparently emphasized the significance of the drug in effectively treating breast cancer, stating that it has the ability to slow the growth of cancer tumors by connecting with two kinases referred as CDK6 and CDK4, which help cancer cells to proliferate after they become over-active.
According to authentic sources, the drug has also been cleared by the European Commission as an initial endocrine mode of treating the postmenopausal women, who are suffering from metastatic breast cancer, along with aromatase inhibitor. However, the drug is not yet officially approved for treatment.
